Quality of claims, references and the presentation of risk results in medical journal advertising: A comparative study in Australia, Malaysia and the United States

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Othman, Noordin ^a,b   Vitry, Agnes I ^a   Roughead, Elizabeth E ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; AUSTRALIA; COMPARATIVE STUDY; LETTER; MALAYSIA; PUBLICATION; STANDARD; UNITED STATES;

ADVERTISING AS TOPIC; AUSTRALIA; MALAYSIA; PERIODICALS AS TOPIC; UNITED STATES;

EID: 77952693555     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-294     Document Type: Article

References (43)

1. How is research evidence used to support claims made in advertisements for wound care products? JC Dumville ES Petherick S O'Meara P Raynor N Cullum, Journal of Clinical Nursing 2009 18 1422 1429 10.1111/j.1365-2702.2008.02293.x 18717743
2. Claims in advertisements for antihypertensive drugs in a Dutch medical journal. JP Greving P Denig D de Zeeuw FM Haaijer-Ruskamp, Journal of Hypertension 2007 25 713 722 10.1097/HJH.0b013e328012662a 17278989
3. Trends in antihypertensive drug advertising, 1985-1996. TJ Wang JC Ausiello RS Stafford, Circulation 1999 99
4. Scientific Versus Commercial Sources of Influence on the Prescribing Behavior of Physicians. J Avorn M Chen R Hartley, American Journal of Medicine 1982 73 4 8 10.1016/0002-9343(82)90911-1 7091173
5. The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns - Theres No Such Thing as a Free Lunch. JP Orlowski L Wateska, Chest 1992 102 270 273 10.1378/chest.102.1.270 1623766
6. Interactions of doctors with the pharmaceutical industry. MA Morgan J Dana G Loewenstein S Zinberg J Schulkin, Journal of Medical Ethics 2006 32 559 563 10.1136/jme.2005.014480 17012493
7. World Medicines Situation. http://www.searo.who.int/LinkFiles/Reports- World-Medicines-Situation.pdf
8. Worldwide survey on national controls of pharmaceutical advertising and promotion. http://www.topra.org/files/2005N11-Focus-02.pdf
9. Effective drug regulation. http://whqlibdoc.who.int/hq/2002/9241562064. pdf
10. Pharmaceutical Associations of Malaysia. http://www.phama.org.my/index. cfm?&menuid=10
11. Medicines Australia. Code of Conduct Edition 15. http://www. medicinesaustralia.com.au/pages/page254.asp
12. Pharmacy Service Division. Medicine Advertisement Board. http://www.pharmacy.gov.my/index.cfm?&menuid=11
13. U.S. Food and Drug Administration, Center of Drug Evaluation and Research Handbook. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM198415. pdf
14. Prescription Drug Advertising: Questions and Answers. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ UCM076768.htm
15. FDA's Oversight of the Promotion of Drugs for Off-Label Uses. http://www.gao.gov/new.items/d08835.pdf
16. Pharmaceutical advertisement claims in Australian medical publications. TW Loke FC Koh JE Ward, Medical Journal of Australia 2002 177 291 293 12225274
17. Pharmaceutical Advertisements in Australian Medical Publications - Have They Improved. ED Carandang RFW Moulds, Medical Journal of Australia 1994 161
18. The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. RJ Cooper DL Schriger, Canadian Medical Association Journal 2005 172 487 491 10.1503/cmaj.1031940 15710940
19. Pharmaceutical Advertisements in Leading Medical Journals - Experts Assessments. MS Wilkes BH Doblin MF Shapiro, Annals of Internal Medicine 1992 116 912 919 1580449
20. Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. N Othman A Vitry EE Roughead, PLoS ONE 2009 4 6350 10.1371/journal.pone.0006350 19623259
21. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat.[see comment]. A Barratt PC Wyer R Hatala T McGinn AL Dans S Keitz V Moyer GG For Evidence-Based Medicine Teaching Tips Working Group, CMAJ Canadian Medical Association Journal 2004 171 353 358 10.1503/cmaj.1021197 (Pubitemid 39127990)
22. Perception of risk information. Similarities and differences between Danish and Polish general practitioners. J Nexoe AM Oltarzewska J Sawicka-Powierza J Kragstrup IS Kristiansen, Scandinavian Journal of Primary Health Care 2002 20 183 187 10.1080/028134302760234663 12389758
23. GPs' and physicians' interpretation of risks, benefits and diagnostic test results. RF Heller JE Sandars L Patterson P McElduff, Fam Pract 2004 21 155 159 10.1093/fampra/cmh209 15020384
24. How patient outcomes are reported in drug advertisements - Review of Canadian medical journals. J Lexchin, Canadian Family Physician 1999 45 1213 1216 10349065
25. Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. KS Lankinen T Levola K Marttinen I Puumalainen A Helin-Salmivaara, Pharmacoepidemiology and Drug Safety 2004 13 789 795 10.1002/pds.1017 15486957
26. Evidence-based advertising? A survey of four major journals. DR Gutknecht, J Am Board Fam Pract 2001 14 197 200 11355052
27. American Family Physician. http://search.rja-ads.com/index.lasso
28. Department of Health and Ageing. Schedule of Pharmaceutical Benefits. http://www.pbs.gov.au/html/home
29. Product information: A pharmaceutical industry perspective. HO Wooller, Australian Prescriber 1995 18 19 21
30. Product information: what does it define? ML Mashford, Australian Prescriber 1994 17 39 41
31. How to use the evidence: assessment and application of scientific evidence. http://www.nhmrc.gov.au/publications/synopses/cp69syn.htm
32. Understanding interobserver agreement: the kappa statistic. AJ Viera JM Garrett, 2005 37 360 363 15883903
33. The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry.[comment]. C Wick M Egger S Trelle P Juni MF Fey, Annals of Oncology 2007 18 1580 1582 10.1093/annonc/mdm402 17761713
34. The accuracy of psychiatric medication advertisements in medical journals.[see comment]. GI Spielmans SA Thielges AL Dent RP Greenberg, Journal of Nervous & Mental Disease 2008 196 267 273 10.1097/NMD.0b013e31816a436b (Pubitemid 351548726)
35. Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. P McGettigan J Golden J Fryer R Chan J Feely, British Journal of Clinical Pharmacology 2001 51 184 189 10.1111/j.1365-2125.2001.01332.x 11259994
36. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. DK Rohra AH Gilani IK Memon G Perven MT Khan H Zafar R Kumar, Journal of Pharmacy and Pharmaceutical Sciences 2006 9 50 59 16849008
37. The case for medical journal advertising. http://www.rxpromoroi.org/ index.html
38. Influences on GPs' decision to prescribe new drugs - the importance of who says what. H Prosser S Almond T Walley, Family Practice 2003 20 61 68 10.1093/fampra/20.1.61 12509373
39. Data on file cited in pharmaceutical advertisements: What are they? http://www.ama-assn.org/public/peer/dath.htm
40. Evidence based advertising - Half of drug advertisements in BMJ over six months cited no supporting evidence. S Smart C Williams, British Medical Journal 1997 315 1622 1623 9437302
41. Accuracy of pharmaceutical advertisements in medical journals. P Villanueva S Peiro J Librero I Pereiro, Lancet 2003 361 27 32 10.1016/S0140-6736(03)12118-6 12517463
42. Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study. B Montgomery P Mansfield G Spurling A Ward, BMC Public Health 2008 8 167 10.1186/1471-2458-8-167 18492241
43. One resident perspective: Resident education and the pharmaceutical industry: One resident perspective: Resident education and the pharmaceutical industry. CR Grudzen, Annals of Emergency Medicine 2005 45 27 31 10.1016/j.annemergmed.2004.09.018 15635304